UNCY Shareholder Alert: November 2, 2026 Lead Plaintiff Deadline in Unicycive Therapeutics, Inc. Securities Class Action - Contact SueWallSt

SueWallSt (Levi & Korsinsky) issued a shareholder alert for Unicycive Therapeutics, publicizing a securities class action with a November 2, 2026 lead plaintiff deadline. The suit names CEO Shalabh Gupta and CFO John Townsend individually under Section 20(a) control-person claims, alleging they oversaw disclosures claiming a third-party manufacturer made significant progress toward FDA compliance without verifying it by inspection. The release reiterates that UNCY fell 39.1% to $4.69 on June 30, 2026 after the FDA issued a second Complete Response Letter.

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.